J 2023

European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

VALENT, Peter, Karin HARTMANN, Patrizia BONADONNA, Wolfgang SPERR, Marek NIEDOSZYTKO et. al.

Basic information

Original name

European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

Authors

VALENT, Peter, Karin HARTMANN, Patrizia BONADONNA, Wolfgang SPERR, Marek NIEDOSZYTKO, Hanneke C KLUIN-NELEMANS, Olivier HERMINE, Karl SOTLAR, Gregor HOERMANN, Boguslaw NEDOSZYTKO, Sigurd BROESBY-OLSEN, Roberta ZANOTTI, Magdalena LANGE, Michael DOUBEK (203 Czech Republic, belonging to the institution), Knut BROCKOW, Ivan ALVAREZ-TWOSE, Judit VARKONYI, Selim YAVUZ, Gunnar NILSSON, Deepti RADIA, Clive GRATTAN, Juliana SCHWAAB, Theo GILLEN, Hanneke N G Oude ELBERINK, Hans HAEGGLUND, Frank SIEBENHAAR, Emir HADZIJUSUFOVIC, Vito SABATO, Jiří MAYER (203 Czech Republic, belonging to the institution), Andreas REITER, Alberto ORFAO, Hans-Peter HORNY, Massimo TRIGGIANI and Michel AROCK

Edition

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, AMSTERDAM, ELSEVIER, 2023, 2213-2198

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 9.400 in 2022

RIV identification code

RIV/00216224:14110/23:00131385

Organization unit

Faculty of Medicine

UT WoS

001023706800001

Keywords in English

Mast cells; Mastocytosis; Mast cell activation dis-orders; MCAS; ECNM

Tags

Tags

International impact, Reviewed
Změněno: 9/8/2023 09:24, Mgr. Tereza Miškechová

Abstract

V originále

In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders. The ECNM also organized annual meetings and several working conferences, thereby supporting the license (http://creativecommons.org/licenses/by/4.0/). (J Al-Clin Immunol Pract 2023;11:1706-17)